Gilead Sciences (NASDAQ:GILD) Stock Rating Upgraded by Leerink Partners

Gilead Sciences (NASDAQ:GILD) was upgraded by equities research analysts at Leerink Partners from a “market perform” rating to an “outperform” rating in a research note issued to investors on Monday, Marketbeat reports. The firm presently has a $96.00 price objective on the biopharmaceutical company’s stock, up from their previous price objective of $74.00. Leerink Partners’ target price points to a potential upside of 8.89% from the company’s current price.

GILD has been the subject of a number of other reports. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research note on Thursday, August 15th. Barclays lifted their target price on shares of Gilead Sciences from $76.00 to $84.00 and gave the stock an “equal weight” rating in a research note on Monday, October 7th. Truist Financial lifted their target price on shares of Gilead Sciences from $82.00 to $83.00 and gave the stock a “hold” rating in a research note on Thursday, August 15th. BMO Capital Markets lifted their target price on shares of Gilead Sciences from $85.00 to $94.00 and gave the stock an “outperform” rating in a research note on Thursday, October 17th. Finally, Wells Fargo & Company upgraded shares of Gilead Sciences from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $78.00 to $100.00 in a research note on Monday, October 7th. Ten analysts have rated the stock with a hold rating, eleven have given a buy rating and three have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Gilead Sciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $86.85.

Gilead Sciences Stock Performance

GILD stock opened at $88.16 on Monday. The firm has a market cap of $109.83 billion, a price-to-earnings ratio of 244.89, a PEG ratio of 2.98 and a beta of 0.18. The firm has a 50-day simple moving average of $81.61 and a two-hundred day simple moving average of $73.07. Gilead Sciences has a one year low of $62.07 and a one year high of $88.36. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.95 and a current ratio of 1.14.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating the consensus estimate of $1.61 by $0.40. The business had revenue of $6.95 billion during the quarter, compared to analyst estimates of $6.64 billion. Gilead Sciences had a net margin of 3.79% and a return on equity of 29.34%. On average, equities analysts forecast that Gilead Sciences will post 3.78 EPS for the current fiscal year.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total transaction of $167,660.00. Following the sale, the insider now directly owns 100,189 shares in the company, valued at $8,398,843.87. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Gilead Sciences news, insider Johanna Mercier sold 29,357 shares of the business’s stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the sale, the insider now directly owns 78,127 shares in the company, valued at $6,545,480.06. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total transaction of $167,660.00. Following the sale, the insider now owns 100,189 shares in the company, valued at $8,398,843.87. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 36,847 shares of company stock valued at $3,033,340 over the last 90 days. 0.16% of the stock is owned by insiders.

Institutional Trading of Gilead Sciences

A number of large investors have recently made changes to their positions in GILD. &PARTNERS purchased a new stake in shares of Gilead Sciences during the first quarter worth approximately $309,000. Dynamic Advisor Solutions LLC increased its stake in shares of Gilead Sciences by 1.9% during the first quarter. Dynamic Advisor Solutions LLC now owns 65,669 shares of the biopharmaceutical company’s stock worth $4,810,000 after buying an additional 1,221 shares during the period. Beech Hill Advisors Inc. increased its stake in shares of Gilead Sciences by 4.0% during the first quarter. Beech Hill Advisors Inc. now owns 15,047 shares of the biopharmaceutical company’s stock worth $1,102,000 after buying an additional 585 shares during the period. F&V Capital Management LLC increased its stake in Gilead Sciences by 1.6% in the first quarter. F&V Capital Management LLC now owns 141,455 shares of the biopharmaceutical company’s stock valued at $10,362,000 after purchasing an additional 2,260 shares during the last quarter. Finally, CIC Wealth LLC increased its stake in Gilead Sciences by 26.4% in the first quarter. CIC Wealth LLC now owns 11,539 shares of the biopharmaceutical company’s stock valued at $845,000 after purchasing an additional 2,411 shares during the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.